Navigation Links
Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Date:11/6/2009

nti-MRSA antibacterials when they wish to switch from intravenous (IV) to oral treatment, a key step prior to a patient being able to be discharged from the hospital.

NXL103, as a member of the Streptogramin class of antibiotics, has a unique mode of action, with its two components acting synergistically to inhibit the bacterial ribosome. Its spectrum of activity indicates its potential to be effective in the treatment of ABSSSI, including those caused by resistant pathogens such as MRSA.

In late 2008, Novexel announced positive results from a Phase II clinical trial evaluating NXL103 in the treatment of community acquired pneumonia (CAP).

Iain Buchanan, Novexel's CEO, said, "The start of this Phase II trial with NXL103 is another important step in the growth of the company. There is a clear need for products that can be used to manage the release of patients from hospital by allowing them to be switched from intravenous to oral therapy."

Notes to Editors

About NXL 103

NXL103 is a novel oral antibiotic made up of two streptogramin antibiotics, linopristin and flopristin, which act synergistically to inhibit the bacterial ribosome. NXL103 is a bactericidal antibiotic and in vivo studies have shown that this novel antibiotic is not affected by either beta-lactam or common macrolide resistance mechanisms. Positive results for a Phase II trial with NXL103 in the treatment of community acquired pneumonia (CAP) were reported towards the end of 2008. NXL103 is currently in a Phase II trial for the treatment of ABSSSI.

About ABSSSI

ABSSSI (Acute Bacterial Skin and Skin Structure Infections) are infections that involve deeper tissue or require surgical intervention (e.g. cellulitis, major cutaneous abscesses, and infected wounds) or are associated with a significant underlying disease that complicates response to therapy. A variety of pathogens may
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
2. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
3. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
4. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
5. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
6. AMT Starts Development LPLChip(TM) With Progenika
7. American Association for Homecare Proposes Strong Anti-Fraud Measures in Medicare, Applauds HHS Testimony Today That Pledges to "Stop Fraud Before it Starts"
8. R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
9. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
10. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2010)... NEW YORK, Sept. 3 The QUAD ... houses, presents the New York premiere of the provocative ... (102 minutes), directed and produced by Dr. D. ... Rutledge, a California physician specializing in preventative medicine, chronicles ... DDT in 1972, a ban inspired by the first ...
(Date:9/3/2010)... 3 The Medical Affairs function arguably ... organization, with heavy responsibilities across areas such as ... education. These areas must operate effectively for new ... is one of the challenges facing the Medical ... different roles across the organization. ...
(Date:9/3/2010)... PR Issued on September 1 for the Stock... -- JERUSALEM, September 3, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Breaking Medicine Technology:3 BILLION AND COUNTING Opens in New York at The QUAD Cinema 23 BILLION AND COUNTING Opens in New York at The QUAD Cinema 3Medical Affairs Report Outlines Resource Needs for Group Success 2Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 2Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 3Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 4Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 5Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 6Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 7Lo Cest Offers a Free Download of a New Bible for the Gay Community 66834 1Lo Cest Offers a Free Download of a New Bible for the Gay Community 66834 2Agility Consulting Partners with pan 28Performance Assessment Network 29 to Bring Custom Private Label Assessment Capability to Human Resource Profes 66829 1Agility Consulting Partners with pan 28Performance Assessment Network 29 to Bring Custom Private Label Assessment Capability to Human Resource Profes 66829 2New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act 66824 1New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act 66824 2New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act 66824 3
... Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... (FDA) has granted Orphan,Drug Designation for IPLEX(TM) for ... currently conducting a 24-week Phase III,enabling trial for ... grant of,approximately $2.1 million from the Muscular Dystrophy ...
... Calif., Dec. 18 Epeius Biotechnologies,Corporation announced ... Certificate of,Product Registration for Rexin-G(R) from the ... the commercialization of its lead product as ... spectrum of intractable cancers.,Developed as a tumor-targeted ...
Other Medicine Technology:Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 2Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 3ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer 2ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer 3
(Date:9/3/2010)... first clinical trials on a new investigational drug being ... have been successfully completed. , Completion of the initial ... first prepared by researchers at Cardiff University,s Welsh School ... becoming an approved medicine have significantly improved. , ... C, which can lead to liver cancer, cirrhosis and ...
(Date:9/2/2010)... is yet no straightforward way to determine the ... radiation therapies such as stereotactic radiation therapy, used ... high-dose brachytherapy for prostate and other cancers., Radiation ... Center-Arthur G. James Cancer Hospital and Richard J. ... problem by developing a new mathematical model that ...
(Date:9/2/2010)... , , THURSDAY, Sept. 2 (HealthDay News) -- As the ... implemented, many small businesses in the United States will ... a new report shows. During the first phase ... workers will be eligible for these tax credits, according ... "The new law is likely to have a ...
(Date:9/2/2010)... 2 September, 2010 - Elsevier announced today the ... European Menopause and Andropause Society (EMAS) in the ... common management problems in the post-reproductive health of ... the menopause in the context of obesity, epilepsy, ... has summary recommendations as a quick aid for ...
(Date:9/2/2010)... HealthDay Reporter , , WEDNESDAY, Sept. 1 (HealthDay ... stimulating activities have pros and cons when it comes ... with prior research, the study finds that such mental ... normal old age. But folks who loved these ... once symptoms of dementia began to set in, the ...
Breaking Medicine News(10 mins):Health News:First clinical trials successfully completed on potent new hepatitis C drug 2Health News:New model may simplify high-dose radiosurgery planning 2Health News:Health Care Reform Helps Small Businesses Offer Coverage: Report 2Health News:Health Care Reform Helps Small Businesses Offer Coverage: Report 3Health News:Health Care Reform Helps Small Businesses Offer Coverage: Report 4Health News:EMAS publishes position statements about the post-reproductive health of women 2Health News:Mental 'Exercise' May Only Hide Signs of Alzheimer's 2Health News:Mental 'Exercise' May Only Hide Signs of Alzheimer's 3
... 12 The Female Health Company (NYSE Alternext: ... (FDA) Obstetrics and Gynecology Devices Advisory Committee has unanimously voted ... is approvable with a single condition. , ... the product is approvable with the condition that the FC2 ...
... 12 Access MediQuip, LLC, the nation,s ... device management,solutions to the healthcare industry, announced ... national contract for device benefit management services.,The ... Inc. to deliver,implantable device management solutions to ...
... in combination with ribavirin for previously untreated children with ... , KENILWORTH, N.J., Dec. 12 ... announced that the U.S. Food and Drug Administration (FDA) ... REBETOL(R) (ribavirin, USP) combination therapy for use in previously ...
... Dec. 12 Laura Rogers, project director for the ... issued the following statement regarding the U.S. Food and ... off-label usage of certain antibiotics in animal agriculture: , ... antibiotics in animal agriculture helps fuel the increase in ...
... Center in conjunction with Sodexo Health Care Services is pleased ... the original certified kosher hot food vending machine. UH ... state of Ohio, offering patients and their caregivers around the ... , University Hospitals prides itself on the ...
... Insurance,Company (John Hancock) is reinforcing its commitment to ... requirements through an,affiliation with the ClearCert Clearinghouse. ... the year and effective January 1, 2009,will only ... Since beginning ...
Other Medicine News:Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5Health News:Access MediQuip and WellPoint Finalize First National Contract for Implantable Medical Devices 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:Statement From The Pew Charitable Trusts on the U.S. Food and Drug Administration's Reversal on Antibiotics Safeguards in Animal Farming 2Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 2Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 3Health News:John Hancock Expands LTC Training Effort with ClearCert High Usage By Producers and Streamlines Process for Insurers 2Health News:John Hancock Expands LTC Training Effort with ClearCert High Usage By Producers and Streamlines Process for Insurers 3
Inquire...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
Inquire...
... a compact system featuring,easy setup and flow ... allowing the use of less,expensive disposable tubing ... office or hospital use, the,PSI-TEC III Infiltrator ... - 5" (w) X 8" (l) X ...
Medicine Products: